The Future of Melanoma: What to Anticipate in 2023 with Neoadjuvant and Adjuvant Pembrolizumab

The Future of Melanoma: What to Anticipate in 2023 with Neoadjuvant and Adjuvant Pembrolizumab

The Future of Melanoma: What to Anticipate in 2022Подробнее

The Future of Melanoma: What to Anticipate in 2022

WCH23: What’s New and Hot in MelanomaПодробнее

WCH23: What’s New and Hot in Melanoma

#ESMO22 Highlights on neoadj. vs adjuvant pembrolizumab in resected stage III-IV melanoma:SWOG S1801Подробнее

#ESMO22 Highlights on neoadj. vs adjuvant pembrolizumab in resected stage III-IV melanoma:SWOG S1801

Highlights in melanoma at AACR 2023Подробнее

Highlights in melanoma at AACR 2023

AACR 2023 highlights on advances in the treatment of resected high-risk melanoma with Jeffrey WeberПодробнее

AACR 2023 highlights on advances in the treatment of resected high-risk melanoma with Jeffrey Weber

Neoadjuvant Therapy and Adjuvant Therapy (pre and post-surgery) for MelanomaПодробнее

Neoadjuvant Therapy and Adjuvant Therapy (pre and post-surgery) for Melanoma

Advances in utilizing neoadjuvant immunotherapy in melanomaПодробнее

Advances in utilizing neoadjuvant immunotherapy in melanoma

Expert Report on novel data in (neo)adjuvant treatment of melanoma from ASCO 2022Подробнее

Expert Report on novel data in (neo)adjuvant treatment of melanoma from ASCO 2022

Melanoma | 2022 OneOncology ConferenceПодробнее

Melanoma | 2022 OneOncology Conference

NADINA: promising neoadjuvant immunotherapy strategies for melanomaПодробнее

NADINA: promising neoadjuvant immunotherapy strategies for melanoma

Emerging Melanoma Therapies & Clinical Trials to WatchПодробнее

Emerging Melanoma Therapies & Clinical Trials to Watch

The future of adjuvant therapy in melanomaПодробнее

The future of adjuvant therapy in melanoma

Results from the KEYNOTE-716: Pembrolizumab versus placebo after complete resection of high-risk...Подробнее

Results from the KEYNOTE-716: Pembrolizumab versus placebo after complete resection of high-risk...

Updates in Melanoma: 2023 West OncologyПодробнее

Updates in Melanoma: 2023 West Oncology

Results from KEYNOTE-716: adjuvant therapy with pembrolizumab in high-risk stage II melanomaПодробнее

Results from KEYNOTE-716: adjuvant therapy with pembrolizumab in high-risk stage II melanoma

KEYNOTE-716: Longer follow up supports pembrolizumab use in stage IIB/IIC melanomaПодробнее

KEYNOTE-716: Longer follow up supports pembrolizumab use in stage IIB/IIC melanoma

How Melanoma is Treated in 2023Подробнее

How Melanoma is Treated in 2023

The personalization of neoadjuvant immunotherapy in stage III melanomaПодробнее

The personalization of neoadjuvant immunotherapy in stage III melanoma

KEYNOTE-716: adjuvant pembrolizumab for high-risk melanomaПодробнее

KEYNOTE-716: adjuvant pembrolizumab for high-risk melanoma